Dan Ollendorf, MPH | Authors

HARRIS TEETER PHARMACY 37

150 GRANT HILL LN

Articles

Impact of Uracil/Tegafur Plus Oral Calcium Folinate on Resource Utilization

July 01, 1999

Data from a multinational phase III trial were analyzed to evaluate the use of in- and outpatient services for 373 patients with metastatic colorectal cancer being administered uracil/tegafur (in a molar ratio of 4:1 [UFT]) plus